Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2017-01-31

Clinical Trial Update: An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus

View source ↗

Summary

Observational study update of patients with Type 1 or Type 2 diabetes treated with NovoMix 30 or Levemir.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Levemir (insulin detemir)
  • NovoMix 30 (insulin aspart protamine fixed-dose combination)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Status: COMPLETED